The European Medicines Agency (EMA) is re-examining its approach to drug safety. The 2026 pharmacovigilance (PV) framework marks significant progress in using real-world evidence (RWE) to monitor medicines and inform regulatory decisions in the European Union (EU).
Earlier, drug safety monitoring relied primarily on clinical trial data and adverse event reports (ADRs). RWE is now essential to Pharmacovigilance. It offers insights from electronic health records, registries, and insurance claims.
How helpful is Real-World Evidence (RWE)?
RWE consists of clinical findings drawn from real-world data (RWD) collected outside traditional clinical trials. RWE and RWD sources showcase how medicines react in routine patient care.
They offer a wider perspective on their effects across diverse populations over time. Regulators, including the EMA, are realizing that incorporating RWE into pharmacovigilance (PV) processes improves timeliness.
The upcoming EMA guidelines on the Real-world Data (RWD) clarify that RWE is intended to supplement, not replace, traditional safety evidence. The EMA guidelines stress that RWE can support
- signal detection,
- effectiveness assessments, and
- benefit-risk evaluations throughout a medicine’s lifecycle.
What does it mean for MAHs?
The EMA framework sets out new compliance requirements and responsibilities for Marketing Authorisation Holders (MAHs), regarding real-world evidence (RWE).
Enhanced Signal Detection and Assessment
MAHs must now incorporate RWE into their pharmacovigilance (PV) systems for signal detection and assessment. It is beyond relying on reporting systems like EudraVigilance.
They are required to actively monitor a wider range of RWD sources and combine these with internal safety data to identify new risks more efficiently.
Transparent Study Registration and Reporting
EMA and the Heads of Medicines Agencies have established central RWD Catalogues for MAHs to register real-world studies and submit related data. These catalogues boost transparency and enable regulators and stakeholders to track both regulator-led and company-led research.
Quality and Methodical Standards
MAHs must ensure that any RWE submitted for regulatory purposes meets strict standards. Draft guidance on the quality of real-world data (RWD), as part of the wider data quality framework, outlines how RWD should be evaluated for
- relevance,
- completeness, and
- reliability before use in regulatory decisions.
Enhanced Pharmacovigilance (PV) Processes
As per the recent pharmacovigilance rules, including the 2025/1466 Regulation, MAHs must revise their internal SOPs and clearly assign responsibility for collecting, analyzing, and submitting RWE, including when collaborating with subcontractors and external partners.
To conclude, the evolving EMA framework indicates that the future of RWE in EU pharmacovigilance depends on collaboration among regulators, MAHs, healthcare providers, and data holders. As analytic technologies advance and data networks such as DARWIN EU expand, RWE will play a greater role in identifying safety signals and improving risk management. It strengthens the evidence base for regulatory decisions.
In this new era, Marketing Authorization Holders (MAHs) who develop strong RWE strategies aligned with EMA’s 2026 pharmacovigilance framework and align with the 2025 real-world data guidelines will be more likely to
- maintain compliance,
- improve safety monitoring, and
- deliver safer medicines to patients across the EU.
Consult a Regulatory expert to learn more about RWE and RWD best practices.